403 related articles for article (PubMed ID: 17955831)
1. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
2. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
Siguret V
Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
4. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
Siguret V; Pautas E; Gouin-Thibault I
Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
[TBL] [Abstract][Full Text] [Related]
5. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
8. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
Scibona P; Redal MA; Garfi LG; Arbelbide J; Argibay PF; Belloso WH
Genet Mol Res; 2012 Jan; 11(1):70-6. PubMed ID: 22290467
[TBL] [Abstract][Full Text] [Related]
10. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
[TBL] [Abstract][Full Text] [Related]
11. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics aspects of oral anticoagulants therapy.
Militaru FC; Vesa SC; Pop TR; Buzoianu AD
J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
Loriot MA; Beaune P
Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of coumarinic oral anticoagulants.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
[TBL] [Abstract][Full Text] [Related]
17. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
[TBL] [Abstract][Full Text] [Related]
18. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
19. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
20. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
